---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003374"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:16:36.769409+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rhythm terminates RareStone license for IMCIVREE in China; reacquires rights for $6.3M

## Summary
- Termination of 2021 Exclusive License and Share Purchase agreements with RareStone Group Ltd.
- Rhythm pays $6.3M repayment of upfront payment; returns all RareStone shares for no consideration.
- Reacquires full rights to IMCIVREE (setmelanotide) in mainland China, Hong Kong, and Macau.
- Global trial for hypothalamic obesity on track for Q2 2025 topline data readout.

## SEC filing metadata
- accession: 0001558370-25-003374
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02, 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000155837025003374/0001558370-25-003374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000155837025003374/rytm-20250314x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003374
- JSON: https://secwatch.observer/filing/0001558370-25-003374.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.